ADAshkan Delavari

Ashkan Delavari

*This is an algorithmically generated author record based on publicly available information.

Ashkan Delavari has a total of 4 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Recently Developed Synthetic Inhibitors for Major Depressive Disorder Treatment

    by Tahmineh Mokhtari, Asma Momeni, Fatemeh Sheikhbahaei, Ashkan Delavari, Changbin Ke

    Major depressive disorder (MDD) pathophysiology extends beyond traditional monoaminergic mechanisms to include neuroinflammation, oxidative stress, mitochondrial dysfunction, and impaired neuroplasticity. This chapter comprehensively reviews emerging synthetic inhibitors targeting these non-monoaminergic pathways. Key therapeutic classes include NLRP3 inflammasome inhibitors, TNF-α antagonists, soluble epoxide hydrolase (sEH) inhibitors, NADPH oxidase (NOX) inhibitors, PARP inhibitors, and modulators of glycogen synthase kinase-3 (GSK-3) and Rho-associated protein kinase (ROCK). Preclinical evidence demonstrates robust efficacy in reversing depression-like behaviors and restoring synaptic plasticity. While several candidates show favorable pharmacokinetic profiles, clinical translation remains limited, necessitating optimized CNS penetration, biomarker-driven trials, and personalized treatment approaches for treatment-resistant depression.